Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03204981 · ClinicalTrials.gov registry record · NA
Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias
A NA study, sponsored by Vivek Reddy.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT03204981: Completed NA study, sponsored by Vivek Reddy.
NCT03204981 is a NA study that has completed, run by Vivek Reddy. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03204981, a NA study, has completed, sponsored by Vivek Reddy.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will examine the safety and efficacy of intramural needle ablation (INA) in the treatment of intramural ventricular arrhythmias in patients for whom standard RF ablation has been unsuccessful. The clinical team hypothesize that the increased current density and improved rates of transmural lesion creation seen with intramural needle ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.
Primary Outcome
Number of participants with VT and number of participants with PVCs who had freedom from ventricular arrhythmia at 6 months for participants who had ablation performed using the experimental Needle ablation catheter versus standard ablation catheter. Needle - patient had ablation performed using the experimental Needle ablation catheter. Registry - patient had ablation using a standard ablation catheter and did not need additional ablation using the Needle catheter.
Interventions
- PROCEDURE Ablation
- DEVICE Intramural Needle Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2021-04-20 |
| Phase | NA |
What the finished NCT03204981 record still lists
NCT03204981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Ablation is the first listed.
NCT03204981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03204981 about?
NCT03204981 is a clinical study titled "Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias". This study will examine the safety and efficacy of intramural needle ablation (INA) in the treatment of intramural ventricular arrhythmias in patients for whom standard RF ablation has been unsuccessful. The clinical team hypothesize that the increased current density and improved rates of transmura...
What is the current status of trial NCT03204981?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2017-10-17. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT03204981?
The interventions under investigation include: Ablation (PROCEDURE), Intramural Needle Ablation (DEVICE).
Who is sponsoring clinical trial NCT03204981?
This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03204981's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI